Anabel Flores Zamora

Anabel Flores Zamora

Auto-generated profile, based on publicly available information

Anabel Flores Zamora

Branch Clinical Research. Laboratory of Molecular Neurobiology and Neurochemistry of Addiction, National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City, Mexico

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Human Vaccines
Verified
Journal Article
Closed access
PDF file
BABenito Anton
Benito Anton
ASAlberto Salazar
Alberto Salazar
AFAnabel Flores
Anabel Flores
MMMaura Matus
Maura Matus
RMRodrigo Marin
Rodrigo Marin
Philippe LeffPhilippe Leff
Philippe Leff
Current pharmacotherapies for treating morphine/heroin dependence are designed to substitute or block addiction by targeting the drug itself rather than the brain. Heroin addict is still being exposed to addictive opiates, and consequently may develop tolerance to and experience withdrawal and drug´s toxic effects from the treatment with high incidence of relapse to addictive drug consumption. As for other drugs of abuse, an alternative approach for morphine/heroin addiction is an antibody-based antagonism of heroin´s brain entry. This review summarizes the literature examining important aspects of neurobiological and pharmacological processes involved in opiate dependence. Thereafter, classical pharmacological interventions for opiate dependence treatment and its major clinical limitations are reviewed. Finally, relevant preclinical studies are examined for comparisons in the design, use, immunogenic profile and efficacy of several models of morphine/heroin vaccine as immunologic interventions on the pharmacokinetics and behavioral of morphine/heroin in the rat as animal model.

1 August 2017 in Psychiatry Research
Verified
Journal Article
Closed access
SBSusana Barbosa-Méndez
Susana Barbosa-Méndez
MMMaura Matus-Ortega
Maura Matus-Ortega
AFAnabel Flores-Zamora
Anabel Flores-Zamora
NJNoe Jurado
Noe Jurado
Alberto Salazar-JuarezAlberto Salazar-Juarez
Alberto Salazar-Juarez

2 February 2010 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
BABenito Anton
Benito Anton
Philippe LeffPhilippe Leff
Philippe Leff
JMJoseph J. Meissler
Joseph J. Meissler
JCJuan C. Calva
Juan C. Calva
RARodolfo Acevedo
Rodolfo Acevedo
TEToby K. Eisenstein
Toby K. Eisenstein

15 May 2017 in FEBS Letters
Verified
Journal Article
Open access
PDF file
MMMaura E. Matus‐Ortega
Maura E. Matus‐Ortega
PGPhilippe Leff Gelman
Philippe Leff Gelman
JCJuan C. Calva‐Nieves
Juan C. Calva‐Nieves
AFAnabel Flores‐Zamora
Anabel Flores‐Zamora
ASAlberto Salazar‐Juárez
Alberto Salazar‐Juárez
BABenito Antón‐Palma
Benito Antón‐Palma
Endomorphins (EMs) have been proposed as the endogenous ligand agonists of the μ‐opioid receptor; however, no propeptide precursor protein for EMs has been identified. Here, to identify the presumed precursor of EMs, we designed an immunoscreening assay using specific affinity‐purified rabbit antisera raised against synthetic EMs in a whole‐mouse brain cDNA library. Following this approach, we identify a DNA sequence encoding a protein precursor, which we name proMexneurin, that contains three different peptide sequences: Mexneurin‐1 (an EM‐like peptide), Mexneurin‐2, and Mexneurin‐3, a peptide which appears to be unrelated to EMs. RT‐PCR analysis and in situ hybridization reveal a widespread distribution of proMexneurin mRNA throughout the mouse brain. Both Mexneurin‐1 and Mexneurin‐3 peptides display biological activities in the mouse CNS.

13 October 2015 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
BPBenito Antón Palma
Benito Antón Palma
Philippe LeffPhilippe Leff
Philippe Leff
MRMayra Medecigo Ríos
Mayra Medecigo Ríos
JNJuan Carlos Calva Nieves
Juan Carlos Calva Nieves
RORodolfo Acevedo Ortuño
Rodolfo Acevedo Ortuño
Alberto Salazar-JuarezAlberto Salazar-Juarez
Alberto Salazar-Juarez
Alpha (α)-amidation of peptides is a mechanism required for the conversion of prohormones into functional peptide sequences that display biological activities, receptor recognition and signal transduction on target cells. Alpha (α)-amidation occurs in almost all species and amino acids identified in nature. C-terminal valine amide neuropeptides constitute the smallest group of functional peptide compounds identified in neurosecretory structures in vertebrate and invertebrate species. The α-amidated isoform of valine residue (Val-CONH2) was conjugated to KLH-protein carrier and used to immunize mice. Hyperimmune animals displaying high titers of valine amide antisera were used to generate stable hybridoma-secreting mAbs. Three productive hybridoma (P15A4, P17C11, and P18C5) were tested against peptides antigens containing both the C-terminal α-amidated (–CONH2) and free α-carboxylic acid (−COO−) isovariant of the valine residue. P18C5 mAb displayed the highest specificity and selectivity against C-terminal valine amidated peptide antigens in different immunoassays. P18C5 mAb-immunoreactivity exhibited a wide distribution along the neuroaxis of the rat brain, particularly in brain areas that did not cross-match with the neuronal distribution of known valine amide neuropeptides (α-MSH, adrenorphin, secretin, UCN1-2). These brain regions varied in the relative amount of putative novel valine amide peptide immunoreactive material (nmol/μg protein) estimated through a fmol-sensitive solid-phase radioimmunoassay (RIA) raised for P18C5 mAb. Our results demonstrate the versatility of a single mAb able to differentiate between two structural subdomains of a single amino acid. This mAb offers a wide spectrum of potential applications in research and medicine, whose uses may extend from a biological reagent (used to detect valine amidated peptide substances in fluids and tissues) to a detoxifying reagent (used to neutralize exogenous toxic amide peptide compounds) or as a specific immunoreagent in immunotherapy settings (used to reduce tumor growth and tumorigenesis) among many others.